Live
PharmaVoiceFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotechEndpoints NewsM&A isn’t just for big pharma. Mid-size companies are stepping up deal huntsLabiotechCAR-T therapy for stiff person syndrome nears approvalIlluminaHere Are Friday’s Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More - 24/7 Wall St.Endpoints NewsAndrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirementEndpoints News#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes liveFierceBiotechAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospectsLabiotechFreeze variability, not progress: strengthen your cell therapy supply chain from the startEndpoints NewsSupreme Court preserves mail access for abortion pillFierceBiotechAardvark to dig into phase 3 data early after FDA imposes holdSiemens HealthineersSiemens Healthineers Wins Key US Clearances As Valuation Gap Widens - simplywall.stBioNTechBioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends - AD HOC NEWS
Illumina Mar 31, 2026

Assenagon Asset Management S.A. Trims Holdings in Illumina, Inc. $ILMN - MarketBeat

Assenagon Asset Management S.A. Trims Holdings in Illumina, Inc. $ILMN - MarketBeat

Original
Body unavailable. Use the original source.